Mama

Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-002821-39
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Ana Ferreira	Recrutamento	2017-002821-39

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar do Porto Largo do Prof. Abel Salazar 4099-001, Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-004869-27
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Marta Ferreira	Recrutamento	2017-004869-27
Centro Hospitalar Universitário Lisboa Norte Hospital de Santa Maria Av. Prof. Egas Moniz 1649-035 Lisboa - Portugal	Dra. Leonor Ribeiro	Recrutamento	2017-004869-27
Fundação Champalimaud Avenida Brasília 1400-038 Lisboa - Portugal	Dra. Fátima Cardoso	Recrutamento	2017-004869-27

A randomized, multicenter, open-label cross-over study to evaluate patient preference and satisfaction of subcutaneous administration of the fixed-dose combination of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Susana Sousa	Recrutamento	2018-002153-30

Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Universitário do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Dra. Noémia Afonso	Recrutamento	2017-003131-11
Centro Hospitalar de Vila Nova de Gaia/Espinho Rua Conceição Fernandes, s/n 4434-502 Vila Nova de Gaia - Portugal	Dr. António Moreira Pinto	Recrutamento	2017-003131-11
Fundação Champalimaud Av. Brasília 1400-038 Lisboa	Dra. Fátima Cardoso	Recrutamento	2017-003131-11
Hospital de Braga Sete Fontes - São Victor 4710- 243 Braga - Portugal	Dra. Catarina Portela	Recrutamento	2017-003131-11
Hospital Beatriz Ângelo Avenida Carlos Teixeira, nº 3 2674-514 Loures - Portugal	Prof. Dr. José Luís Passos Coelho	Recrutamento	2017-003131-11
Unidade Local de Saúde de Matosinhos Hospital Pedro Hispano Rua de Dr. Eduardo Torres Senhora da Hora - Portugal	Dra. Matilde Salgado	Recrutamento	2017-003131-11

A Phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician's choice for HER2- low, unresectable and/or metastatic breast cancer subjects

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira Guimarães Rua dos Cutileiro, 114 Creixomil Guimarães - Portugal	Dra. Ilda Faustino	Recrutamento	2018-003069-33
Unidade Local de Matosinhos, EPE Hospital Pedro Hispano Rua Dr. Eduardo Torres 4464-513 Senhora da Hora - Portugal	Dra. Matilde Salgado	Recrutamento	2018-003069-33

Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active- Controlled, Multicenter Trial

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira Guimarães Rua dos Cutileiro, 114 Creixomil Guimarães - Portugal	Dra. Alexandra Teixeira	Recrutamento	2018-002990-24

An single arm open-label multi-centre extension study of pertuzumab administered as a single agent or in combination with other anti-cancer therapies in patients previously enrolled in a Hoffmann-La Roche sponsored pertuzumab study

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Centro Hospitalar Lisboa Norte Hospital de Santa Maria Av. Egas Moniz 1649-028 Lisboa - Portugal	Dr. Luís António Marques Costa	Recrutamento	2014-002048-42

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast Cancer(TNBC) (CAPItello-290)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Senhora da Oliveira Guimarães Rua dos Cutileiro, 114 Creixomil Guimarães - Portugal	Dra. Camila Coutinho	Recrutamento	2018-004687-64

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada 100 1500-650 Lisboa - Portugal	Dra. Mónica Nave	Recrutamento	2017-000419-17
Hospital Beatriz Ângelo Av. Carlos Teixeira, 3 2674-214 Loures - Portugal	Prof. Dr. José Luís Passos Coelho	Recrutamento	2017-000419-17

Targeting EGFR/ERBB2 with Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA trial)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada 100 1500-650 Lisboa - Portugal	Dra. Catarina Pulido	Recrutamento	2019-000710-11

A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of adjuvant atezolizumab or placebo and trastuzumab emtansine for her2-positive breast cancer at high risk of recurrence following preoperative therapy

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital Beatriz Ângelo Av. Carlos Teixeira, 3 2674-514, Loures - Portugal	Dra. Mafalda Casa-Nova	Recutamento	2020-003681-40

A phase III randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of gdc-9545 combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor-positive, her2-negative locally advanced or metastatic breast cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada, 100 1500-650, Lisboa - Portugal	Dra. Catarina Pulido	Recrutamento	2020-000119-66

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7FL)

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada, 100 1500-650, Lisboa - Portugal	Dra. Mónica Nave	Recrutamento	2019-002469-37

A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer with Brain Metastases and/or Leptomeningeal Carcinomatosis

Contactos do Centro de Ensaio	Investigador Responsável	Estado	Nº EudraCT
Hospital da Luz Av. Lusíada, 100 1500-650, Lisboa - Portugal	Dra. Mónica Nave	Recrutamento	2019-001739-29